In today’s briefing:
- Facebook 1Q22: TikTok-Ified
- Teladoc Health Inc (TDOC US): 1Q22 Results Review- Revenue Missed, 2022 Guidance Reduced
- Could Starlink Go Public Through a SPAC?
- Raiders of the Lost Disney
- ACCO: Normalizing with Growth
- Align Technology (ALGN US) Q1 Results: Both Revenue and Earnings Miss, First Time in Last Two Years
Facebook 1Q22: TikTok-Ified
- Solid earnings call heightened our conviction in Facebook as a terrific long for the next year.
- Reels monetization headwind will become a tailwind… just a question of when. TikTok threat is real, but Facebook knows how to clone other’s innovations.
- Apple IDFA issues not worsening, Facebook will figure this out eventually.
Teladoc Health Inc (TDOC US): 1Q22 Results Review- Revenue Missed, 2022 Guidance Reduced
- Teladoc Health, Inc. (TDOC US) reported Q1 results, in-line with its prior guidance. However, 2022 guidance cut has played the spoilsport.
- Teladoc shares plummeted more than 40% in 2022 to trade near 52-week low. With the near-term noises persist, shares will need time to recover.
- With the current market dynamics in certain areas of operation not in favor of Teladoc, recent downfall in shares does not represent an attractive buying opportunity.
Could Starlink Go Public Through a SPAC?
- Rumors of a Starlink IPO/SPAC deal have been slowly gaining momentum since 2020, as the company has continued to scale rapidly.
- The deal speculation has only intensified in recent months, as investors seem convinced that the company could go public through a merger with a Chamath Palihapitiya-led SPAC.
- Starlink, which is currently estimated to be worth between $30 and $40 billion, could be one of the largest and most prolific SPAC transactions to date.
Raiders of the Lost Disney
- The magic of Disney is lost. It is time to find it again.
- In this insight, we discuss the major reasons of why we believe Disney could be the next major M&A target after Twitter Inc (TWTR US).
- Disney needs to focus on its core competency which is providing great contents rather than publicly confronting politicians on highly sensitive issues.
ACCO: Normalizing with Growth
- ACCO experienced a recovery in all its segments in the first quarter 2022, especially from COVID-19 related closures in Mexico and Brazil
- ACCO reported comparable sales rose 11 percent compared to the prior year, but foreign exchange limited the quarter’s performance
- ACCO is continuing to project a higher free cash flow than in 2021, which would be used to reduce its debt level.
Align Technology (ALGN US) Q1 Results: Both Revenue and Earnings Miss, First Time in Last Two Years
- Align Technology (ALGN US) reported underwhelming Q1 results. Both revenue and earnings missed consensus and were down sequentially.
- Sequential results primarily reflect lower volumes mainly due to continued impact of the COVID-19 causing lesser patient traffic and practice closure.
- Due to increased uncertainty across all its operating markets, the company suspended 2022 revenue guidance. Earlier, Align guided for 20–30% y/y revenue growth in 2022.
Before it’s here, it’s on Smartkarma
